When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease?
Journal Title: Нирки - Year 2017, Vol 6, Issue 1
Abstract
International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.
Authors and Affiliations
D. D. Ivanov
Keywords
Related Articles
- EP ID EP208749
- DOI 10.22141/2307-1257.6.1.2017.93781
- Views 93
- Downloads 0
New era of dialysis: expanded haemodialysis (HDx)
The article is addressed to practical physicians involved in renal replacement therapy, mainly haemodialysis (HD). The article presents a new method for haemodialysis — expanded haemodialysis, assesses its efficiency, an...
Modern Philosophy of Knowledge Transfer in Postgraduate Medical Education
.
Infections of Urinary Tract in Children: 2012 Updating
.
European Association of Urology, 2017 Paediatric Urology Guidelines. Urological infections. Summary of changes
.
Efficacy of Low-Protein Diet and Ketoanalogues of Amino Acids as a Complex of Renoprotective Agents in the Therapy of Chronic Kidney Disease
.